201 related articles for article (PubMed ID: 34099032)
1. Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.
Aksnes M; Aass HCD; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
Transl Neurodegener; 2021 Jun; 10(1):18. PubMed ID: 34099032
[TBL] [Abstract][Full Text] [Related]
2. Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimer's Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort.
Aksnes M; Aass HCD; Tiiman A; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
J Alzheimers Dis; 2022; 86(3):1459-1470. PubMed ID: 35213378
[TBL] [Abstract][Full Text] [Related]
3. Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort.
Aksnes M; Müller EG; Tiiman A; Edwin TH; Terenius L; Revheim ME; Vukojević V; Bogdanović N; Knapskog AB
J Alzheimers Dis; 2020; 77(2):831-842. PubMed ID: 32741818
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease.
Aksnes M; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
Front Aging Neurosci; 2020; 12():608628. PubMed ID: 33488383
[TBL] [Abstract][Full Text] [Related]
5. Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.
Tiiman A; Jelić V; Jarvet J; Järemo P; Bogdanović N; Rigler R; Terenius L; Gräslund A; Vukojević V
J Alzheimers Dis; 2019; 68(2):571-582. PubMed ID: 30814355
[TBL] [Abstract][Full Text] [Related]
6. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline.
Taipa R; das Neves SP; Sousa AL; Fernandes J; Pinto C; Correia AP; Santos E; Pinto PS; Carneiro P; Costa P; Santos D; Alonso I; Palha J; Marques F; Cavaco S; Sousa N
Neurobiol Aging; 2019 Apr; 76():125-132. PubMed ID: 30711675
[TBL] [Abstract][Full Text] [Related]
7. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression.
Begcevic I; Tsolaki M; Brinc D; Brown M; Martinez-Morillo E; Lazarou I; Kozori M; Tagaraki F; Nenopoulou S; Gkioka M; Lazarou E; Lim B; Batruch I; Diamandis EP
F1000Res; 2018; 7():1012. PubMed ID: 30191060
[No Abstract] [Full Text] [Related]
8. Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid.
Rauchmann BS; Sadlon A; Perneczky R;
J Alzheimers Dis; 2020; 73(4):1615-1626. PubMed ID: 31958095
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.
Pyykkö OT; Lumela M; Rummukainen J; Nerg O; Seppälä TT; Herukka SK; Koivisto AM; Alafuzoff I; Puli L; Savolainen S; Soininen H; Jääskeläinen JE; Hiltunen M; Zetterberg H; Leinonen V
PLoS One; 2014; 9(3):e91974. PubMed ID: 24638077
[TBL] [Abstract][Full Text] [Related]
10. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
11. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
13. Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study.
Pikwer A; Castegren M; Namdar S; Blennow K; Zetterberg H; Mattsson N
J Neuroinflammation; 2017 Sep; 14(1):193. PubMed ID: 28962579
[TBL] [Abstract][Full Text] [Related]
14. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.
Brosseron F; Traschütz A; Widmann CN; Kummer MP; Tacik P; Santarelli F; Jessen F; Heneka MT
Alzheimers Res Ther; 2018 Feb; 10(1):25. PubMed ID: 29482610
[TBL] [Abstract][Full Text] [Related]
15. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
16. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
18. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
19. Systemic Inflammation and Multimodal Biomarkers in Amnestic Mild Cognitive Impairment and Alzheimer's Disease.
Magalhães TNC; Weiler M; Teixeira CVL; Hayata T; Moraes AS; Boldrini VO; Dos Santos LM; de Campos BM; de Rezende TJR; Joaquim HPG; Talib LL; Forlenza OV; Cendes F; Balthazar MLF
Mol Neurobiol; 2018 Jul; 55(7):5689-5697. PubMed ID: 29039020
[TBL] [Abstract][Full Text] [Related]
20. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
